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Assessment of a home-based standing frame programme 
in people with progressive multiple sclerosis (SUMS): 
a pragmatic, multi-centre, randomised, controlled trial 
and cost-effectiveness analysis
Jennifer Freeman, Wendy Hendrie, Louise Jarrett, Annie Hawton, Andrew Barton, Rachel Dennett, Ben Jones, John Zajicek, Siobhan Creanor
Summary
Background People severely impaired with progressive multiple sclerosis spend much of their day sitting, with very few 
options to improve motor function. As a result, secondary physical and psychosocial complications can occur. Effective 
and feasible self-management strategies are needed to reduce sedentary behaviour and enhance motor function. In 
this study, we aimed to assess the clinical and cost effectiveness of a home-based, self-managed, standing frame 
programme.
Methods SUMS was a pragmatic, multicentre, randomised controlled superiority trial of people with progressive 
multiple sclerosis and severe mobility impairment, undertaken in eight centres from two regions in the UK. The 
study had assessor-blinded outcome assessments with use of clinician-rated and patient-rated measures at baseline, 
20 weeks, and 36 weeks. After baseline assessment, participants were randomised (1:1) by computer-generated 
assignment to either a standing frame programme plus usual care or usual care alone. The intervention consisted of 
two home-based physiotherapy sessions (60 min each) to set up the standing frame programme, supported by 
six follow-up telephone calls (15 min per call). Participants were asked to stand for 30 min, three times per week over 
20 weeks, and encouraged to continue in the longer term, although no further physiotherapy support was provided. 
The primary clinical outcome was motor function measured by the Amended Motor Club Assessment (AMCA) score 
at week 36, analysed in the modified intention-to-treat population (excluding only patients who were deemed ineligible 
after randomisation, those who withdrew from the trial and were unwilling for their previously collected data to be 
used, or those who did not provide baseline and week 36 measurements). A 9-point AMCA score change was 
considered clinically meaningful a priori. Adverse events were collected through a daily preformatted patient diary 
throughout the 36 weeks and analysed in the modified intention-to-treat population. An economic assessment 
established the resources required to provide the standing frame programme, estimated intervention costs, and 
estimate cost effectiveness. This trial is registered with the International Standard Randomised Controlled Trials, 
number ISRCTN69614598.
Findings Between Sept 16, 2015, and April 28, 2017, 285 people with progressive multiple sclerosis were screened for 
eligibility, and 140 were randomly assigned to either the standing frame group (n=71) or the usual care group (n=69). 
Of these, 122 completed the primary outcome assessment (61 participants in both groups) for the modified intention-
to-treat analysis. The use of the standing frame resulted in a significant increase in AMCA score compared with that 
for usual care alone, with a fully adjusted between-group difference in AMCA score at 36 weeks of 4·7 points (95% CI 
1·9–7·5; p=0·0014). For adverse events collected through patient diaries, we observed a disparity between the two 
groups in the frequency of short-term musculoskeletal pain (486 [41%] of 1188 adverse events in the standing frame 
group vs 160 [22%] of 736 adverse events in the usual care group), which was potentially related to the intervention. 
The musculoskeletal pain lasted longer than 7 days in five participants (two in the standing frame group and three in 
the usual care group). No serious adverse events related to the study occurred. The standing frame group had a mean 
0·018 (95% CI –0·014 to 0·051) additional quality-adjusted life-years (QALYs) compared with those of the usual care 
group, and the estimated incremental cost-per-QALY was approximately £14 700.
Interpretation The standing frame programme significantly increased motor function in people with severe 
progressive multiple sclerosis, although not to the degree that was considered a priori as clinically meaningful. The 
standing frame is one of the first physiotherapy interventions to be effective in this population. We suggest that the 
programme is feasible as a home-based, self-managed intervention that could be routinely implemented in clinical 
practice in the UK.
Funding UK National Institute of Health Research.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
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Introduction
Multiple sclerosis is a progressive, neurological condition 
that affects 2·5 million people worldwide. The disease 
impacts all aspects of patients’ lives, having substantial 
and adverse effects on quality of life. Multiple sclerosis is 
associated with high direct and indirect costs to patients, 
their families, and society. These costs are highly correlated 
with increasing immobility.1
Mobility is a major concern for people with multiple 
sclerosis.2 It is estimated that, within 10–15 years of 
diagnosis, approximately 80% of people will have impaired 
mobility. Eventually, an estimated 25% of patients are 
wheel chair dependent.3 Mobility spans more than walk­
ing, including also standing, transferring, and moving 
in bed.4 These are important activities for maintaining 
independence, particularly for people who are severely 
physic ally impaired. Individuals with pro gressive mul­
tiple sclerosis spend much of their day sitting,5 often 
with reduced ability to change position. In response, 
insidious but preventable secondary complica tions can 
occur, including muscle wasting, reduced skin integ­
rity, spasms, constipation, depression, and low ered self­
esteem.6 These problems can compound the primary 
neurological dis ability, accelerating loss of independence, 
and can even be mistaken for disease progression. 
Furthermore, long periods of sitting time are associated 
with increased risks of morbidity and mortality.5 The 
clinical importance of these issues is underlined by their 
consistent promin ence in policy documents for long­term 
neurological conditions.4,7
Strong evidence exists that increases in physical activity 
can improve mobility and minimise secondary health 
problems in people with mild to moderate multiple 
sclerosis,8 and evidence suggests that this might also be 
the case for people with severe multiple sclerosis.9,10 
Despite this evidence, up to 78% of people with mul­
tiple scler osis do not participate in meaningful physical 
activity.11 There can be considerable barriers to keeping 
active when mobility impairment is severe.12 Interventions 
have typic ally been resource intensive, entailing reg­
ular super vised sessions by a physiotherapist or sports 
therapist, in an outpatient or hospital setting, and relying 
on expen sive equipment that cannot be used in the home 
envir onment.9,10 Moreover, more data are needed regarding 
adherence when supervision ceases.
Finite health­care resources mean that ongoing super­
vision of physical activity programmes is rarely possible. 
Effective self­management strategies, which are low cost 
and realistic to implement, are needed for people with 
severe physical limitations to optimise their engage ment 
in physical activity. Regular supported standing with use of 
standing frames, which can be used within people’s 
homes, is one such option. Standing frames enable indi­
viduals with restricted mobility, balance, or lower limb 
or trunk control the opportunity to spend time in sup­
ported standing. Proposed benefits of standing include 
Research in context 
Evidence before this study
We searched electronic databases (MEDLINE, AMED, CINAHL, 
Embase, PsycINFO, and PEDro) for manuscripts published in 
English and with study populations aged older than 18 years, 
from database inception to Aug 1, 2018. Search terms were 
“multiple sclerosis” and “standing frames”, “standing tables”, or 
“standing wheelchairs”. We also checked the reference lists from 
identified papers and searched ClinicalTrials.gov and the 
International Standard Randomised Controlled Trials registry. No 
adequately powered randomised controlled trials assessing the 
clinical or cost effectiveness of a standing intervention were 
identified. Our search revealed one systematic review of standing 
in people with upper motor neuron disorders that cited a small 
pilot randomised trial in people with multiple sclerosis (n=6) and 
one mixed-methods study (AB case study design plus interviews, 
n=9), neither of which exclusively recruited people with 
progressive multiple sclerosis. To our knowledge, no randomised 
controlled trials of standing frame use in people with multiple 
sclerosis have been undertaken since our literature search.
Added value of this study
To our knowledge, the SUMS study is the largest randomised 
controlled trial assessing physical rehabilitation in people with 
progressive multiple sclerosis. It is the first assessor-blinded, 
multicentre, randomised trial to investigate the clinical and cost 
effectiveness, safety, and tolerability of a supported standing 
frame programme plus usual care versus usual care alone in 
people with progressive multiple sclerosis whose standing 
balance and walking is severely impaired. The standing frame 
programme was well tolerated in people with multiple sclerosis 
who were unable to walk or whose mobility was limited to a 
maximum of 20 m with a bilateral walking aid. The standing 
programme significantly increased motor function in people 
with progressive multiple sclerosis, although not to the degree 
that was considered a priori as clinically meaningful. 
The response of participants varied regarding standing but, on 
average, longer standing times were associated with 
significantly greater improvements in motor function, with the 
confidence intervals containing the a priori clinically meaningful 
improvement. Our cost-effectiveness analysis showed that the 
standing frame programme had an estimated incremental cost 
of approximately £14 700 per quality-adjusted life-year (QALY) 
and a 0·52 to 0·61 probability of being cost effective at the 
National Institute of Health and Care Excellence threshold of 
£20 000–30 000 per QALY.
Implications of all the available evidence
The use of a home-based, self-managed standing frame 
programme could improve motor function in individuals with 
progressive multiple sclerosis. Our study is an important 
addition to the evidence-base for supported standing, for which 
high-level evidence is currently lacking.
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strengthening antigravity muscles, providing prolonged 
weight­bearing muscle stretch, enhancing respiratory 
func tion, and maintaining bone density.6 Although prelim­
inary evidence has shown benefit for their use in people 
with multiple sclerosis,13–15 no appropriately powered 
random ised controlled trials have been done. In line with 
the conclusions of a systematic review6 that such evi dence 
was needed, we aimed to assess whether a home­based 
standing frame programme was clinically effective and 
to explore its cost­effectiveness in people with severe, 
progressive multiple sclerosis.
Methods
Study design and participants
The trial methods, previously published in detail,16 are 
briefly described in line with existing guidelines.17–20 The 
SUMS study was an individually randomised, controlled, 
pragmatic, multi­centre, superiority trial with masked 
outcome assessments in people with progressive mul­
tiple sclerosis. Participants were randomly assigned to 
receive either usual care or usual care plus a standing 
programme, with masked assessments done at baseline, 
20 weeks post­randomisation (aligned with the end of 
the protocol intervention period for those allocated to 
the intervention group), and again 16 weeks afterwards 
(36 weeks post­randomisation).
Participants were recruited through eight health­care 
organisations, including the UK National Health Service 
(NHS) Trusts, social enterprises, and third sector mul tiple 
sclerosis therapy centres, in two regions (Devon–Cornwall 
and East Anglia) of the UK. Individuals were invited 
consecutively until the allocated number of standing 
frames (dependent on commissioning costs) at each 
health­care organisation had been reached. Key inclusion 
criteria were age older than 18 years, a diag nosis of pro­
gressive multiple sclerosis (primary or sec on dary) accord­
ing to McDonald’s criteria,21 and a score of 6·5–8·0 on the 
Expanded Disability Status Scale (EDSS). Key exclusion 
criteria were being within 3 months of ceasing a multiple 
sclerosis disease­modify ing drug, receiving steroid treat­
ment within the preced ing month, or part icipat ing in 
another clinical trial. Full inclusion and exclusion criteria 
are reported in the protocol paper.16
This study was ethically approved by the NHS Health 
Research Authority Committee South West—Frenchay 
Research Ethics Committee (15/SW/0088). Participants 
provided written informed consent before enrolment or 
undertaking any study­related pro cedures. 
People with multiple sclerosis were actively involved 
throughout the study, including in the develop ment of 
the research questions, study design, trial manage ment 
and steering groups, writing of study materials, and 
dissemination activities.
Randomisation and masking
The 1:1 allocation sequence was done with random­sized 
permuted blocks, stratified by region (Devon–Cornwall or 
East Anglia) and baseline EDSS score (≤7·0 or ≥7·5). The 
sequence was computer generated in conjunction with an 
independent statistician who had no further involvement 
in the trial. The randomisation list and the programme 
that generated it were stored in a secure network location 
within the Peninsula Clinical Trials Unit, registered with 
the UK Clinical Research Collaboration, accessible only to 
those responsible for providing the system. Participants 
were randomly assigned after baseline assessment, with 
the masked assessor inputting the participant details 
directly into the randomisation website.
It was not possible to mask trial participants, carers, 
or treating physiotherapists because of the nature of 
the intervention. However, outcome assessors (research 
therapists) were masked to treatment allocation, and all 
assessments were done independently and away from 
the participant’s home. At each assessment timepoint, 
research therapists were asked whether they were un­
masked to group allocation; 114 (89%) of 128 answers at 
week 20 and 110 (87%) of 126 at week 36 were “no”. The 
trial statisticians were masked for the primary analysis of 
the primary outcome.
Procedures
Participants allocated to the standing frame group 
were issued with a wooden Oswestry standing frame 
(Theo Davies & Sons, Wrexham, UK), funded through the 
UK NHS commissioning process and delivered to the 
participant’s home before the first physiotherapy session. 
The person with multiple sclerosis and their standing 
assistant (typically their spouse) engaged in two face­to­
face, home­based, 60­min physiotherapy sessions, aimed 
at setting up, implementing, and progressing the standing 
programme according to ability, supplemented by online 
advice and DVDs. These were supported by six scripted 
telephone calls (15 min per call) that used a behaviour­
change approach22 to increase the participant’s self­
efficacy, intended to enhance long­term engagement.
In line with previous research,14 participants were asked 
to stand in the frame for 30 min three times per week over 
20 weeks, and to record the frequency and duration of 
each stand in a daily diary. This allowed for a graduated 
introduction to standing. At the end of the 20­week period, 
participants were encouraged to continue to regularly 
stand, although no further physiotherapy support was 
provided. On trial completion, participants were able 
to keep the frame, providing they used it at least once 
per week. 
The use of standing frames is a recognised core skill for 
UK­trained neurological physiotherapists. To standardise 
and optimise implementation of the intervention, we 
provided educational materials and assessed fidelity to 
them.16 All participants received their usual health 
and social service input throughout the study period.16 
This input was recorded on a self­report health­care and 
social­care resource form, which included changes in 
medication.
For the Oswestry standing 
frame see http://www.oswestry-
frames.co.uk/
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Figure 1: Trial profile
AMCA=Amended Motor Club Assessment. *One participant did not attend the 20-week assessment but returned for week 36.
285 participants contacted and assessed for eligibility
142 participants screened
140 had baseline assessment and were randomly assigned
2 excluded
 1 mobility level too high
 1 unable to tolerate assessment procedures
71 allocated to standing frame group
71 attended baseline visit and completed AMCA
68 attended week 20 assessment
66 completed AMCA
3 withdrew
 1 stroke
 1 osteopath recommendation
 1 change in disease status
2 attended but did not complete AMCA at week 20
65 attended week 36 assessment
61 completed AMCA
2 withdrew
 1 family bereavement
 1 pain, awaiting foot surgery
1 lost to follow-up
4 attended but did not complete AMCA at week 36
61 included in the modified intention-to-treat 
 population and analysed
69 allocated to usual care group
69 attended baseline visit and completed AMCA
63 attended week 20 assessment
63 completed AMCA
5 withdrew
 3 did not wish to be in control group
 1 breast cancer
 1 family circumstance and bladder infection
1 did not attend assessment at week 20
63 attended week 36 assessment
61 completed AMCA*
1 withdrew
 1 arthritis
2 attended but did not complete AMCA at week 36
61 included in the modified intention-to-treat 
 population and analysed
138 ineligible
 23 no space in house
 21 mobility too high
 4 personal reasons
 2 unlikely to tolerate intervention
 17 mobility too low 
 8 other illness
 3 no standing assistant
 1 musculoskeletal problems
 1 no capacity to consent
 5 risk of being randomised to control group
 1 died 
 3 already had frame
 2 not home enough
 3 did not have progressive multiple sclerosis
 5 another trial
 1 claustrophobia
 4 alemtuzumab
 14 recruitment quota full for allocated health-care
               organisation
 20 recruitment target reached
 5 declined to participate
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Outcomes
Validated outcome measures included clinician­rated 
assessments and self­reported questionnaires. The prim­
ary outcome was motor function as measured by the 
Amended Motor Club Assessment (AMCA) score23 at the 
primary endpoint of 36 weeks post­randomisation. This 
score was developed for use by physiotherapists in a 
clinical setting to assess motor function in people with 
multiple sclerosis and has shown validity, reliability, and 
responsiveness.14,23,24 The AMCA score (range 0–76) is the 
sum of two subscores. The functional activity subscore 
(16 items, each scored 0–3) comprises key functional 
activities of the trunk and lower limbs, such as rolling in 
bed, sit­to­stand, and sitting and standing balance. The 
lower limb movement subscore (14 items, each scored 0–2) 
rates motor impairment by grading hip and knee flexion 
and knee flexion and dorsiflexion in lying, sitting, and 
standing positions.
The secondary outcomes, at weeks 20 and 36, were 
measure ments of explanatory physical impairments 
(length of hip flexors, hamstrings and ankle plantar flex­
ors [manual goniometry], knee extensor strength [hand­
held dynamometer], spasm frequency [Penn Spasm 
Frequency Scale], and forced expiratory volume at 1 s 
[hand­held spirometer]);16 clinical outcomes (bowel and 
bladder control [bladder and bowel control scales], sitting 
balance [modified functional reach in sitting], and falls 
frequency); and quality of life (29­item Multiple Sclerosis 
Impact Scale [MSIS­29, version 2]). AMCA score at 
week 20 and the two AMCA subscores at week 36 were 
also measured as secondary outcomes. Participants were 
classified as fallers if they self­reported falling on 2 or 
more days during three different periods: up to week 20, 
up to week 36, and between weeks 21 and 36.
All participants were asked to record new symptoms, 
falls, and medication changes in a daily preformatted 
diary. Intervention participants were asked to record 
frequency and duration of standing sessions and any 
adverse events they had. A serious adverse event was 
defined as an untoward occurrence that resulted in death, 
was life­threatening, required hospital admission, or was 
Standing 
frame group 
(n=71)
Usual care 
group (n=69)
All (n=140)
Age, years 58·5 
(51·3–66·4)
60·1 
(54·1–66·0)
59·6 
(52·6–66·2)
Mean EDSS score 
(SD; range)
7·3 (0·6; 
6·5–8·0)
7·2 (0·6; 
6·5–8·0)
7·3 (0·6; 
6·5–8·0)
6·5 24 (34%) 18 (26%) 42 (30%)
7·0 11 (15%) 17 (25%) 28 (20%)
7·5 11 (15%) 16 (23%) 27 (19%)
8·0 25 (35%) 18 (26%) 43 (31%)
Sex
Men 31 (44%) 19 (28%) 50 (36%)
Women 40 (56%) 50 (72%) 90 (64%)
Type of multiple sclerosis
Primary progressive 28 (39%) 16 (23%) 44 (31%)
Secondary 
progressive
43 (61%) 53 (77%) 96 (69%)
Most recent relapse
>1 year 62 (87%) 63 (91%) 125 (89%)
Within 3 months 2 (3%) 2 (3%) 4 (3%)
Within 6 months 2 (3%) 0 2 (1%)
Within 12 months 1 (1%) 2 (3%) 3 (2%)
Unknown 4 (6%) 2 (3%) 6 (4%)
Occupation
Unemployed 5 (7%) 3 (4%) 8 (6%)
Student 0 1 (1%) 1 (1%)
Part-time work 2 (3%) 7 (10%) 9 (6%)
Full-time work 1 (1%) 1 (1%) 2 (1%)
Retired due to age 7 (10%) 8 (12%) 15 (11%)
Medically retired 56 (79%) 49 (71%) 105 (75%)
Indoor walking aid
One stick 3 (4%) 2 (3%) 5 (4%)
Two sticks 7 (10%) 8 (12%) 15 (11%)
Frame 27 (38%) 30 (43%) 57 (41%)
Wheelchair 47 (66%) 48 (70%) 95 (68%)
(Table 1 continues in next column)
Standing 
frame group 
(n=71)
Usual care 
group (n=69)
All (n=140)
(Continued from previous column)
Outdoor walking aid
One stick 2 (3%) 2 (3%) 4 (3%)
Two sticks 6 (8%) 6 (9%) 12 (9%)
Frame 11 (15%) 15 (22%) 26 (19%)
Wheelchair 67 (94%) 64 (93%) 131 (94%)
Wheelchair use
None 4 (6%) 4 (6%) 8 (6%)
Occasionally 4 (6%) 3 (4%) 7 (5%)
Monthly 2 (3%) 1 (1%) 3 (2%)
Weekly 13 (18%) 10 (14%) 23 (16%)
Daily 48 (68%) 51 (74%) 99 (71%)
Medical History
None of note 14 (20%) 13 (19%) 27 (19%)
Osteoarthritis 6 (8%) 9 (13%) 15 (11%)
Coronary heart 
disease or 
hypertension
15 (21%) 9 (13%) 24 (17%)
Diabetes 8 (11%) 1 (1%) 9 (6%)
COPD 6 (8%) 1 (1%) 7 (5%)
Migraine 7 (10%) 5 (7%) 12 (9%)
Other neurological 
condition
4 (6%) 3 (4%) 7 (5%)
Depression 27 (38%) 30 (43%) 57 (41%)
Osteoporosis 5 (7%) 8 (12%) 13 (9%)
Other 25 (35%) 23 (33%) 48 (34%)
Data are n (%) or median (IQR), unless otherwise specified. EDSS=Expanded 
Disability Status Scale. COPD=chronic obstructive pulmonary disease. 
Table 1: Demographic data and baseline characteristics
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considered medically significant by the investigator. An 
embedded qualitative component explored the contemp­
oraneous subjective experiences of using a standing 
frame within daily life through audio­recorded diaries by 
a subgroup of intervention participants. These data will 
be reported in a future publication.
Statistical analysis
The target sample size was based on comparing AMCA 
scores at week 36 between allocated groups, adjusting for 
baseline AMCA score, and detecting a minimal clinically 
important difference of 9 points, assuming an estimated 
SD 20 for AMCA score and estimated correlation of 
0·55 between baseline and week 36 AMCA scores.16 The 
detection of a 9­point between­group difference with 
80% power and at a 5% significance level required 
follow­up data from 55 participants per group. We allowed 
for 20% loss to follow­up or non­completion of primary 
outcome and set the recruitment target at 140 participants.
The analyses were pre­specified in a statistical analysis 
plan approved by the trial steering committee before 
analysis started, except for the analysis method for spasm 
frequency. Primary analyses were adjusted for the 
stratification factors (region and baseline EDSS) as fixed 
effects and baseline scores where appropriate (ie, fully 
adjusted models); results adjusted for baseline scores 
alone are also presented. Estimated between­group dif­
ferences are presented with two­sided 95% CIs, with the 
two­sided significance level for hypothesis testing set at 
5%. The analyses were done with Stata SE (version 14.2).
The primary analysis population was defined as all 
participants who completed baseline and 36­week assess­
ments. The primary analysis of the primary out come, 
AMCA score at 36 weeks, followed a modified intention­
to­treat approach, regardless of compliance to the inter­
vention, but did exclude patients who were deemed 
ineligible after randomisation, those who withdrew from 
the trial and were unwilling for their previously collected 
data to be used, or those who did not provide baseline and 
week 36 measurements (ie, there was no imputation of 
missing baseline or week 36 scores for the primary 
analysis), and used an analysis of covariance (ANCOVA) 
approach. As prespecified in the statistical analysis plan, 
Complier Average Causal Effect (CACE) sensitivity analy­
ses were done on the 36­week AMCA scores. This method 
provides an unbiased estim ate of the interven tion effect, 
based on participants who complied with the standing 
intervention protocol.25 The agreed statistical analysis plan 
listed six compliance definitions that could trigger a CACE 
analysis25 (appendix p 2), if at least 20% of participants 
allocated to the intervention group were classed as non­
compliers in the definition. The CACE analysis, triggered 
AMCA score for standing 
frame group (n=71)
AMCA score for usual 
care group (n=69)
AMCA score for compliers AMCA score for non-compliers 
plus usual care group
Fully adjusted 
analysis, mean 
difference 
(95% CI)*
Analysis 
adjusted for 
baseline 
alone, mean 
difference 
(95% CI)
Baseline Week 36 Baseline Week 36 Baseline Week 36 Baseline Week 36
mITT analysis 26·1 (13·9; 
3·0–59·0; 
n=71)†
29·3 (17·2; 
1·0–68·0; 
n=61)†
30·2 (14·6; 
6·0–66·0; 
n=69)†
28·2 (17·0; 
0·0–68·0; 
n=61)†
·· ·· ·· ·· 4·7 (1·9–7·5); 
p=0·0014
4·6 (1·6–7·6); 
p=0·0030
CACE analyses
Best 16 weeks ·· ·· ·· ·· 26·2 (13·7; 
3·0–56·0; 
n=49)†
29·9 (16·0; 
6·0–65·0; 
n=46)†
29·1 (14·6; 
6·0–66·0; n=91)† 
28·4 (17·5; 
1·0–68·0; 
n=76)†
6·1 (2·5–9·8); 
p=0·00094
6·1 (2·2–9·9); 
p=0·0020
Worst 16 weeks ·· ·· ·· ·· 28·2 (13·4; 
8·0–56·0; 
n=36)†
31·6 (16·4; 
8·0–65·0; 
n=35)†
28·1 (14·7; 
3·0–66·0; n=104)†
27·9 (17·1; 
1·0–68·0; 
n=87)†
7·9 (3·1–12·8); 
p=0·0013
7·9 (2·8–13·0); 
p=0·0025
Weeks 5–20 ·· ·· ·· ·· 26·7 (14·0; 
3·0–56·0; 
n=46)†
30·5 (15·9; 
6·0–65·0; 
n=43)†
28·8 (14·5; 
6·0–66·0; n=94)†
28·1 (17·5; 
1·0–68·0; 
n=79)† 
6·5 (2·6–10·4); 
p=0·0010
6·5 (2·3–10·6); 
p=0·0022
Best 32 weeks ·· ·· ·· ·· 26·6 (14·0; 
3·0–56·0; 
n=46)†
32·4 (16·6; 
6·0–65·0; 
n=43)†
32·4 (16·6; 
6·0–65·0; n=43)†
28·0 (14·5; 
6·0–66·0; 
n=94)†
6·5 (2·7–10·4); 
p=0·00077
6·5 (2·4–10·5); 
p=0·0016
Worst 32 weeks ·· ·· ·· ·· 28·4 (13·9; 
8·0–56·0; 
n=36)†
32·4 (16·6; 
6·0–65·0; 
n=35)†
28·0 (14·5; 
3·0–66·0; n=104)†
27·5 (16·9; 
1·0–68·0; 
n=87)†
7·9 (3·1–12·7); 
p=0·0013
7·8 (2·8–12·9); 
p=0·0025
Weeks 5–36 ·· ·· ·· ·· 27·3 (13·8; 
3·0–56·0; 
n=42)†
31·9 (15·7; 
6·0–65·0; 
n=41)†
28·5 (14·6; 
4·0–66·0; n=98)†
27·5 (17·4; 
1·0–68·0; 
n=81)†
6·8 (2·8–10·8); 
p=0·00078
6·8 (2·6–11·0); 
p=0·0016
Data are mean (SD; range), unless otherwise specified. Mean differences in both analyses are between the standing and usual care group. *Adjusted for baseline AMCA Score, region and Expanded Disability 
Status Scale category.† n is the total number of participants who provided data at that timepoint. 
Table 2: Primary outcome of Amended Motor Club Assessment (AMCA) scores at 36 weeks: primary modified intention-to-treat (mITT) analysis and Complier Average Causal Effect 
(CACE) sensitivity analyses
For the statistical analysis plan 
see https://www.plymouth.ac.
uk/research/sums
See Online for appendix
Articles
742 www.thelancet.com/neurology   Vol 18   August 2019
for all six definitions, used two­stage least squares instru­
mental variable regression, with treat ment allocation as 
the instrument for the binary com pliance variable and 
adjustment for baseline AMCA score, region, and EDSS 
category.25
A repeated­measures model was fitted to the post­
baseline AMCA scores, including adjustment for 
baseline AMCA score, stratification variables, and the 
inter act ion term between allocated group and timepoint. 
Between­group pairwise comparisons at 20 and 36 weeks 
were calculated with use of marginal linear predictions 
and CIs from the fitted model.
All secondary outcomes were analysed on a modified 
intention­to­treat basis, with an ANCOVA approach, for 
both fully adjusted models and models with adjustment 
for base line measures alone, except spasm frequency 
and falls. Ordinal logistic regression was prespecified 
for the analysis of the 5­level Penn Spasm Frequency 
Scale; however, because of insufficient numbers in some 
of the response categories, a dichotomisation of no 
spasms–mild spasms versus infrequent spasms–more 
than 1 per h–more than 10 per h was agreed. We used 
logistic regression to analyse the dichotomised Penn 
Spasm Frequency Scale and the binary outcome of fallers–
non­fallers with adjustment for stratification factors.
We did a within­trial cost­effectiveness analysis. This 
estimated the additional costs of delivering the inter­
vention, costs associated with health, social care, carer 
and patient resource use, and quality­adjusted life­years 
(QALYs) over the 36­week trial period. QALYs were 
estimated with use of self­report EQ­5D­5L (the five­level 
version of EQ­5D, a standardised generic instrument for 
measuring health status) data collected at baseline and at 
20­week and 36­week follow­up, and by applying the so­
called cross­walk algorithm3 to provide QALY weights 
from the UK general population valuation survey of the 
three­level version of EQ­5D.4 The primary perspective 
was the UK NHS and Personal Social Services (PSS), with 
a broader societal perspective considered in sensitivity 
analyses. Detailed methods are provided in the appendix 
(pp 3–9).
Standing 
frame group 
(n=71)
Usual care 
group (n=69)
Adverse events lasting <7 days 1188 736
Pain 551 180
Categorised according to organ classification*
Musculoskeletal 486 160
Neurological 16 12
Abdominal 9 6
Gynaecological 0 2
Renal 2 0
Respiratory 1 0
Spasms 231 197
Fatigue 60 184
Urinary tract infection 45 36
Numbness or sensory disturbance 41 33
Tremor or shaking 7 24
Weakness 24 23
Constipation or diarrhoea 7 17
Vertigo 22 9
Virus 31 5
Chest Infection 16 5
Leg or back stiffness or tightness 23 2
Headache 3 3
Visual disturbance 3 3
Seizures 0 2
Balance problems 5 2
Loss of bladder control 0 2
Slurred speech 0 1
Multiple sclerosis relapse 1 1
Confusion 0 1
Rash 0 1
Toe infection 0 1
Shingles 0 1
Bladder spasms 2 1
Blood in urine 0 1
Nausea or vomiting 2 1
Low sodium 1 0
Ankle swelling 4 0
Depression 1 0
Shortness of breath 3 0
Tennis elbow 1 0
Low blood pressure 3 0
Bruising 1 0
(Table 3 continues in next column)
Standing 
frame group 
(n=71)
Usual care 
group (n=69)
(Continued from previous column)
Participants reporting adverse events 
lasting ≥7 days (number of participants)
28 21
Urinary tract infection 10 4
Chest infection 10 5
Nervous system 4 6
Spasms 2 4
Fatigue 2 1
Weakness 0 1
Stiff legs 1 0
Bowel difficulties 0 3
Infection 1 0
Psychiatric (depression) 1 0
Musculoskeletal pain† 2 3
*Pain categorised according to the MedDRA organ classification system. 
†Usual care group: coccyx pain (lasting 18 days), heel pain (9 days), and hip pain 
(22 days); standing frame group: back pain (lasting 11 days) and joint ache 
(14 days). 
Table 3: Self-reported adverse events (new symptoms) according to 
allocated group
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This trial is registered with the International Standard 
Randomised Controlled Trials, number ISRCTN69614598.
Role of the funding source
This was an investigator­initiated study. The sponsor and 
funders of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. All authors had full access to all the data in the 
study and responsibility for writing the manuscript. The 
corresponding author had final responsibility for the 
decision to submit for publication.
Results
Between Sept 16, 2015, and April 28, 2017, we screened 
285 potential participants. After screening, 140 participants 
were randomly assigned to either use a standing frame in 
addition to usual care (n=71) or to usual care alone (n=69; 
figure 1). Baseline characteristics were broadly consistent 
across the allocated groups (table 1). Some imbalances in 
sex and type of multiple sclerosis were observed: the pro­
portion of men allocated to the standing frame group was 
higher than that allocated to the usual care group, and 
the proportion of participants with primary pro gressive 
multiple sclerosis was higher in the standing frame group 
than in the usual care group (table 1). Additionally, there 
was an imbalance in baseline AMCA score, with a lower 
mean score in the standing frame group compared to that 
in the usual care group (table 2).
At the primary endpoint, 36 weeks post­randomisation, 
the pooled (ie, across both groups) SD of the AMCA score 
was 16·9 points, with a correlation between baseline and 
week 36 AMCA score of 0·86. Individual­level changes in 
the score between baseline and week 36 assessments by 
allocated group are shown in appendix (p 10). The AMCA 
score at week 36 was significantly higher in the standing 
frame group than the usual care group, with a fully 
adjusted between­group mean difference of 4·7 points 
(95% CI 1·9–7·5, p=0·0014; table 2). Results of the 
analysis adjusted for baseline AMCA score alone were 
similar.
Analyses of 36­week AMCA subscores and short­term 
AMCA scores at 20 weeks showed significant fully adjusted 
between­group mean differences in favour of the standing 
frame group (appendix pp 11, 14). We observed short­term, 
statistically significant differences in favour of the standing 
frame group at 20 weeks in hip goniometry, knee extensor 
strength, and in both the physical and psychological 
components of the MSIS­29 scale (appendix pp 11–13). 
We also observed longer term significant differences, 
at 36 weeks, in hip and ankle goniometry in favour of 
the standing frame group; the short­term differences 
in MSIS­29 scale were not sus tained at 36 weeks 
(appendix pp 14–16). The proportion of participants having 
two or more falls during weeks 21–36 was significantly 
lower in the standing frame group, with odds ratio of 0·43 
(95% CI 0·20–0·94, p=0·035), but there was no significant 
between­group difference over weeks 1–20 or the full 
36­week study period. Fall ing days per person­year, pooled 
across both groups, was 9·9 during 36 weeks.
18 serious adverse events were reported in 15 partici­
pants (seven participants in the usual care group and eight 
in the standing frame group; three participants each had 
two serious adverse events), none of which occurred 
during or in relation to the standing frame intervention. 
These serious adverse events were in line with expectations: 
urinary tract infections (n=8), cardio vascular events (stroke 
[n=2] and arrhythmia [n=1]), breast cancer (n=1), falls (n=3, 
of whom two participants fractured a hip), respiratory 
infections (n=2), and burns (n=1). In two individuals, 
pressure sores on the heels developed after hospital 
admission. For one of these participants, this resulted in 
the inability to continue using the frame after hospital 
discharge, despite regular use pre­hospitalisation.
Our adverse event reporting was based on so­called 
new symptoms, recorded with pre­formatted daily 
diaries, and is distinct from the serious adverse event 
data. Overall, 1924 symptoms were recorded (1188 in the 
standing frame group and 736 in the usual care group; 
table 3). These were expected in people with multiple 
sclerosis.3 We observed a disparity between the groups in 
the frequency of short­term musculoskeletal pains, such 
as aching leg muscles, which was potentially related to 
the intervention. The musculoskeletal pain lasted for 
longer than 7 days in five individuals (two in the standing 
frame group and three in the usual care group).
Prespecified sensitivity analyses of the primary out come 
with additional adjustment for variables with observed 
Figure 2: Fully adjusted mean difference in Amended Motor Club Assessment (AMCA) score at 36 weeks for 
the primary analysis and Complier Average Causal Effect (CACE) sensitivity analyses
CACE sensitivity analyses done under the six compliance definitions (numbered 1–6). Error bars represent 95% CIs. 
The blue dashed line represents the pre-specified minimal clinically important difference of 9 points on the AMCA 
scale. nI=number of participants in the standing frame group. nTAU=number of participants in the usual care group. 
nC=number of compliers. nNC=number of compliers plus participants in the usual care group.
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baseline imbalance (sex and type of multiple sclerosis) 
were consistent with the primary analysis results. The 
planned CACE sensitivity analyses yielded results con­
sistent with the primary analysis, although, under the 
CACE approach, the average between­group mean differ­
ences were larger and all the CIs included 9·0 (figure 2). 
The repeated­measures modelling gave similar results to 
the primary analysis, with a significant between­group 
difference in mean AMCA score at week 20 of 3·7 points 
(95% CI 1·2–6·2, p=0·004) and at week 36 of 4·5 points 
(2·0–7·0, p<0·001).
The estimated mean intervention cost per participant 
was £808 (SD 91; appendix p 17). The main cost drivers 
were the standing frame (£504) and physiotherapist home 
visits (£76). Mean costs to the NHS–PSS over the follow­up 
period (adjusted for cost at baseline, EDSS category, and 
region) were approximately £539 less for the standing 
frame group than for the usual care group, excluding the 
cost of the intervention itself. With the addition of the 
intervention cost, adjusted mean costs to the NHS–PSS 
were approximately £268 greater for the standing frame 
group (table 4, and appendix pp 18–26). The amount 
of informal care used by our study popu lation was 
substantial, and application of a national average hourly 
rate to this time gave an adjusted informal care cost of 
approximately £3643 less in the standing frame group 
than in the usual care group (table 4; appendix pp 18–26). 
The mean EQ­5D­5L increase from baseline to 36­week 
follow­up was 0·042 for the stand ing frame group and 
0·01 for the usual care group. This equated to an adjusted 
mean of 0·018 (95% CI –0·014 to 0·051) additional QALYs 
over the period of follow­up (table 4).
The cost­per­QALY of the intervention from the 
perspective of the NHS–PSS was approximately £14 700 
(appendix pp 27). Uncertainty around this estimate is 
illustrated in the cost­effectiveness plane of bootstrapped 
replicates of incremental costs and incremental QALYs 
(appendix pp 28). These simulations suggested that, on 
87% of occasions, the standing frame group would have 
greater QALYs over the period of follow­up than those of 
the usual care group. The bootstrap replicates also indi­
cated a 0·52 probability of the intervention being con­
sidered cost­effective at a willingness­to­pay threshold of 
£20 000 per QALY and a 0·61 probability at a threshold 
of £30 000 per QALY. Broadening the analysis perspective 
beyond health and social care, in line with the recom­
mendations of the Second Panel on Cost­Effectiveness 
in Health and Medicine,26 increased the apparent cost­
effectiveness of the intervention.
There were few missing data and thus, we did not use 
multiple imputation. Sensitivity analyses explored the 
broader societal perspective and also took into account 
the 10­year life of the frames and the NHS’s policy of 
equipment re­use. For both scenarios, the interven­
tion appeared dominant in terms of cost­effectiveness 
(appendix pp 27–28).
Discussion
Our results provide high­quality evidence that, compared 
with usual care alone, regular use of frame standing plus 
Standing frame (n=71) Usual care (n=69) Difference adjusted for baseline 
covariates*†
Resource item
Primary care £594·58 (831·29); n=65 £470·46 (681·94); n=62 15·79 (–199·74 to 248·23)
Secondary care £1787·40 (4155·02); n=65 £2074·17 (3836·70); n=62 –284·82 (–1368·04 to 1077·62)
Personal social services £477·58 (1359·09); n=65 £947·28 (3086·93); n=62 –10·78 (–408·81 to 369·46)
Total NHS–PSS (excluding standing frame 
intervention)
£2859·56 (4958·43); n=65 £3491·91 (5408·15); n=62 –539·27 (–1953·60 to 1138·40)
Standing frame intervention £807·74; n=54 ·· ··
Total NHS–PSS £3667·30 (4958·43); n=65 £3491·91 (5408·15); n=62 268·47 (–1093·79 to 2051·38)
Patient personal costs £2999·25 (6951·45); n=65 £2117·50 (3437·69); n=62 709·07 (–998·70 to 2469·58)
Informal care £16 047·16 (9944·57); n=65 £18 624·35 (13 589·22); n=62 –3643·34 (–6020·19 to –1348·18)
Total costs (NHS, PSS, and patient and informal care) £21 905·97 (12 147·65); n=65 £24 233·75 (13 464·93); n=62 –2192·41 (–5755·23 to –1163·43)
EQ-5D-5L values by timepoint
Baseline 0·224 (0·272, range 
–0·352 to 0·813); n=71
0·251 (0·274, range 
–0·265 to 0·778); n=69
··
20 weeks 0·294 (0·269, range 
–0·256 to 0·813); n=68
0·271 (0·304, range 
–0·319 to 0·779); n=63
··
36 weeks 0·266 (0·303, range 
–0·307 to 0·767); n=65
0·262 (0·293, range 
–0·358 to 0·836); n=62
··
QALYs (based on EQ-5D-5L) over the 36-week follow-up 0·189 (0·174, range 
–0·125 to 0·549); n=65
0·183 (0·182, range 
–0·142 to 0·544); n=62
0·018 (–0·014 to 0·051)
Data are mean (SD) or mean (95% CI), unless otherwise specified. *Cost (specific to each cost component) or EQ-5D-5L value at baseline, Expanded Disability Status Scale 
category (≥7·5 to <7·5) at baseline, and region. †Mean (95% CI) from bootstrap with 10 000 replication.
Table 4: Estimated costs and EQ-5D-5L values by group, and adjusted cost and adjusted quality-adjusted life-years (QALYs) differences, over a 36-week 
follow-up
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usual care provides significant improvements in motor 
function (our primary outcome) in people severely 
physically impaired with progressive multiple sclerosis, 
although not to the degree that was considered a priori as 
clinically meaningful. We also found evidence for 
differences in favour of the standing frame group 
regarding hip and ankle joint range and quality of life 
(secondary outcomes). This standing frame intervention 
was shown to be feasible for people with progressive 
multiple sclerosis to self­manage with the help of a 
standing assistant and for physiotherapists to implement 
within routine clinical practice.
Less clearcut is whether the outcome of the standing 
frame intervention was clinically meaningful. Interpretat­
ion is difficult because of the insufficient evidence to 
define what constitutes a minimal clinically important 
difference on the AMCA score. We relied on the only two 
physiotherapy studies we were aware of that had used the 
AMCA score; both suggested that a 9­point improvement 
was clinically relevant in people with severe multiple 
sclerosis.14,24 A 9­point change could mean, for example, 
that a person could have improved so that they could 
balance in sitting to dress themselves (3 points), transfer 
independently (3 points), and stand without having 
to use their hands for balance (3 points). However, an 
improvement in any single one of these functional acti­
vities might constitute a clinically meaningful change. 
This view is supported by the audio narrative accounts of 
the changes undergone by SUMS study participants. 
When considering the design of future studies, further 
explorat ion is needed regarding the minimal clinically 
import ant difference on this measure for severely impaired 
individuals.
Our CACE analysis showed that accounting for 
compliance to the intervention resulted in a larger estim­
ated intervention effect, with the prespecified minimal 
clinically important difference of 9 points on the AMCA 
score contained within the 95% CIs of all six compliance 
definitions. This suggests a positive association between 
compliance with the intervention and the motor benefits 
gained. This is consistent with theoretical expectations 
and with the results of (low methodological quality) 
studies of standing frame use in populations with other 
neurological conditions.6
To sustain any benefits gained from physical activity, 
individuals need to maintain long­term engagement, 
which is a particular challenge for people with a disability.27 
Evidence is scarce regarding long­term adherence in 
people with multiple sclerosis to physical activity interven­
tions; however, non­adherence rates are as high as 80% 
for individuals with chronic conditions for which interven­
tions might aim to slow down decline rather than to cure.27 
Two thirds of the participants in the standing frame group 
continued to stand regularly in the frame during the 
36­week period, which, in light of the literature, we 
consider to be a high proportion. Furthermore, 70% of 
participants who had a standing frame during the study 
requested to keep the frame on completing the study, thus 
further supporting the feasibility and acceptability of the 
intervention.
Behavioural change techniques were an integral 
component of the standing frame intervention. To comple­
ment the physiotherapy advice and support, individuals 
had access to paper­based, DVD, and online resources, 
designed to equip them and their standing assistants with 
the knowledge and skills necessary to undertake this 
activity within their own homes. Aimed at enhancing self­
efficacy,22 this approach was considered essential because 
self­efficacy is a key determinant of physical activity 
behaviour in people with multiple sclerosis28 and is 
typically low.12
Tolerability of an intervention is important for adher ence 
and thus, capturing adverse events potentially associated 
with the intervention was important. We achieved this by 
using daily, self­reported, preformatted diaries. However, 
free­text description of adverse events was often ambig­
uous, making it difficult to determine whether they were 
new symptoms. Therefore, it is challenging to precisely 
state what proportion of these broad­ranging symptoms 
are related to the standing frame intervention. Bias in 
reporting of adverse events is also possible because the 
standing frame group recorded both details of each 
standing session and any new symptoms in the same 
diaries, potentially triggering reporting of new symptoms 
more comprehensively than in the usual care group. 
However, overall, the data suggest that this intervention is 
well tolerated; the adverse events were typically transient 
(lasting less than 7 days), musculo skeletal in nature (aches 
and pains), and occurred early in the programme when 
participants were probably adjust ing to recommencement 
of regular standing. Importantly, physiotherapists should 
inform people that short­term musculoskeletal aches and 
pains might occur and provide education about how to 
manage this. From a methodologi cal perspective, effective 
and reliable systems for collect ing adverse event data in 
rehabilitation trials should be further investigated.
Our study has several strengths. To our knowledge, this 
is the largest randomised controlled physical rehabilitation 
study to date undertaken in severely impaired people with 
progressive multiple sclerosis. It was the first definitive 
multicentre randomised controlled trial to assess the 
clinical and cost effectiveness, safety, and tolerability of a 
home­based, self­managed standing frame programme in 
this population. The study was originally planned to have 
80% power, on the basis of conservative assumptions;16 
with our observed SD being lower and the correlation 
between baseline and week 36 AMCA scores higher than 
anticipated, we were able to estimate the intervention 
effect with increased precision. Our cost­effectiveness 
analysis assumed that a new standing frame would 
be purchased for everyone in the intervention group; 
however, given the NHS policy of equipment re­use, and 
the average 10­year life of a frame, our cost­effectiveness 
estimate is likely to be conservative.
For the audio narratives of the 
SUMS study participants see 
https://www.plymouth.ac.uk/
research/sums
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Another strength of our study is that it was a pragmatic 
trial. To maximise generalisability of the results, we 
minimised our exclusion criteria. The intervention was 
delivered by physiotherapists working within the NHS, 
who did not undergo specific training for this intervention, 
making it likely that similar results would be gained 
on implementation within usual practice. However, we 
should note that our findings cannot automatically be 
generalised to other countries that do not have a similar 
organisational context. The publication of our educational 
resources on a freely available website aims to enhance 
shared, evidence­based, decision making about the effect 
of introducing this intervention to people’s daily lives.
Our study has several limitations. Our primary eco­
nomic outcome measure was QALYs, in line with 
guidance by the National Institute for Health and Care 
Excellence. The difference in EQ­5D­5L scores (used to 
calculate QALYs) between the standing frame and usual 
care groups at 36­weeks did not reach the minimal 
clinically important difference for the EQ­5D­5L score 
described by Marra and colleagues.29 Therefore, it could 
be argued that the QALY gain was not perceptibly 
different from zero, implying that the intervention was 
not cost­effective. However, the standing frame interven­
tion did appear effective from the patient’s perspective 
when considered across outcome measures, specifically 
according to the primary clinical outcome measure. Our 
main analysis might have been restrictive in identifying 
benefits of the intervention, and a broader societal 
perspective might have been preferable.
The usual care group was not offered an intervention 
and hence, we could not exclude that placebo effects 
might have contributed to the benefits experienced by the 
standing frame group. However, the primary outcome 
was clinician­rated and measured by a masked assessor, 
which should reduce the effect of this. Nevertheless, 
further research is needed to disentangle the intrinsic 
effects of standing from non­specific effects due to, for 
example, attention. It is also possible that drug inter­
ventions might have contrib uted to any of the changes 
observed. However, participants were excluded if there 
had been any recent changes in disease­modifying ther­
apies, and they were asked to record any medication 
changes throughout the study period; the two groups 
were balanced in terms of medica tion changes, there­
fore, this is unlikely to account for the between­group 
differences.
In conclusion, there is a paucity of evidence­based, self­
management interventions that are recommended for 
people severely impaired with progressive multiple scler­
osis who have few treatment options available. We hope 
this inter ven tion can now be offered and reimbursed 
more widely as a management option for this population.
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